 | • レポートコード：MRC2-11QY11723 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は中枢神経系疾患治療薬のグローバル市場について調査・分析したレポートです。種類別（抗うつ薬、抗不安薬、抗躁病、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別中枢神経系疾患治療薬の競争状況、市場シェア ・世界の中枢神経系疾患治療薬市場：種類別市場規模 2015年-2020年（抗うつ薬、抗不安薬、抗躁病、その他） ・世界の中枢神経系疾患治療薬市場：種類別市場規模予測 2021年-2026年（抗うつ薬、抗不安薬、抗躁病、その他） ・世界の中枢神経系疾患治療薬市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、オンライン薬局） ・世界の中枢神経系疾患治療薬市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、オンライン薬局） ・北米の中枢神経系疾患治療薬市場分析：米国、カナダ ・ヨーロッパの中枢神経系疾患治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの中枢神経系疾患治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の中枢神経系疾患治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの中枢神経系疾患治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Alkermes、Astrazeneca、Biogen、Bristol Myers Squibb、Lilly、GSK、Merck、Sunovion Pharmaceuticals、Pfizer、Teva、Norvatis ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous system
Market Analysis and Insights: Global Drugs for Central Nervous System Diseases Market
The global Drugs for Central Nervous System Diseases market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drugs for Central Nervous System Diseases market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drugs for Central Nervous System Diseases market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drugs for Central Nervous System Diseases market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drugs for Central Nervous System Diseases market.
Global Drugs for Central Nervous System Diseases Scope and Market Size
Drugs for Central Nervous System Diseases market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Central Nervous System Diseases market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Antidepressants
Anxiolytics
Anti-manic
Other
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Based on regional and country-level analysis, the Drugs for Central Nervous System Diseases market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Drugs for Central Nervous System Diseases market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Alkermes
Astrazeneca
Biogen
Bristol Myers Squibb
Lilly
GSK
Merck
Sunovion Pharmaceuticals
Pfizer
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Antidepressants
1.2.3 Anxiolytics
1.2.4 Anti-manic
1.2.5 Other
1.3 Market by Application
1.3.1 Global Drugs for Central Nervous System Diseases Market Share by Application: 2020 VS 2026
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Central Nervous System Diseases Market Perspective (2015-2026)
2.2 Global Drugs for Central Nervous System Diseases Growth Trends by Regions
2.2.1 Drugs for Central Nervous System Diseases Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Drugs for Central Nervous System Diseases Historic Market Share by Regions (2015-2020)
2.2.3 Drugs for Central Nervous System Diseases Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Central Nervous System Diseases Players by Market Size
3.1.1 Global Top Drugs for Central Nervous System Diseases Players by Revenue (2015-2020)
3.1.2 Global Drugs for Central Nervous System Diseases Revenue Market Share by Players (2015-2020)
3.2 Global Drugs for Central Nervous System Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Drugs for Central Nervous System Diseases Revenue
3.4 Global Drugs for Central Nervous System Diseases Market Concentration Ratio
3.4.1 Global Drugs for Central Nervous System Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Central Nervous System Diseases Revenue in 2019
3.5 Key Players Drugs for Central Nervous System Diseases Area Served
3.6 Key Players Drugs for Central Nervous System Diseases Product Solution and Service
3.7 Date of Enter into Drugs for Central Nervous System Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Central Nervous System Diseases Breakdown Data by Type (2015-2026)
4.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Type (2015-2020)
4.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Type (2021-2026)
5 Drugs for Central Nervous System Diseases Breakdown Data by Application (2015-2026)
5.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Application (2015-2020)
5.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Drugs for Central Nervous System Diseases Market Size (2015-2026)
6.2 North America Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
6.3 North America Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)
6.4 North America Drugs for Central Nervous System Diseases Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Drugs for Central Nervous System Diseases Market Size (2015-2026)
7.2 Europe Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
7.3 Europe Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)
7.4 Europe Drugs for Central Nervous System Diseases Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Drugs for Central Nervous System Diseases Market Size (2015-2026)
8.2 China Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
8.3 China Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)
8.4 China Drugs for Central Nervous System Diseases Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Drugs for Central Nervous System Diseases Market Size (2015-2026)
9.2 Japan Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
9.3 Japan Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)
9.4 Japan Drugs for Central Nervous System Diseases Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Drugs for Central Nervous System Diseases Market Size (2015-2026)
10.2 Southeast Asia Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
10.3 Southeast Asia Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)
10.4 Southeast Asia Drugs for Central Nervous System Diseases Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11Key Players Profiles
11.1 Alkermes
11.1.1 Alkermes Company Details
11.1.2 Alkermes Business Overview
11.1.3 Alkermes Drugs for Central Nervous System Diseases Introduction
11.1.4 Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2015-2020))
11.1.5 Alkermes Recent Development
11.2 Astrazeneca
11.2.1 Astrazeneca Company Details
11.2.2 Astrazeneca Business Overview
11.2.3 Astrazeneca Drugs for Central Nervous System Diseases Introduction
11.2.4 Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
11.2.5 Astrazeneca Recent Development
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen Drugs for Central Nervous System Diseases Introduction
11.3.4 Biogen Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
11.3.5 Biogen Recent Development
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Details
11.4.2 Bristol Myers Squibb Business Overview
11.4.3 Bristol Myers Squibb Drugs for Central Nervous System Diseases Introduction
11.4.4 Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
11.4.5 Bristol Myers Squibb Recent Development
11.5 Lilly
11.5.1 Lilly Company Details
11.5.2 Lilly Business Overview
11.5.3 Lilly Drugs for Central Nervous System Diseases Introduction
11.5.4 Lilly Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
11.5.5 Lilly Recent Development
11.6 GSK
11.6.1 GSK Company Details
11.6.2 GSK Business Overview
11.6.3 GSK Drugs for Central Nervous System Diseases Introduction
11.6.4 GSK Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
11.6.5 GSK Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Drugs for Central Nervous System Diseases Introduction
11.7.4 Merck Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
11.7.5 Merck Recent Development
11.8 Sunovion Pharmaceuticals
11.8.1 Sunovion Pharmaceuticals Company Details
11.8.2 Sunovion Pharmaceuticals Business Overview
11.8.3 Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Introduction
11.8.4 Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
11.8.5 Sunovion Pharmaceuticals Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Drugs for Central Nervous System Diseases Introduction
11.9.4 Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
11.9.5 Pfizer Recent Development
11.10 Teva
11.10.1 Teva Company Details
11.10.2 Teva Business Overview
11.10.3 Teva Drugs for Central Nervous System Diseases Introduction
11.10.4 Teva Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
11.10.5 Teva Recent Development
11.11 Norvatis
10.11.1 Norvatis Company Details
10.11.2 Norvatis Business Overview
10.11.3 Norvatis Drugs for Central Nervous System Diseases Introduction
10.11.4 Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
10.11.5 Norvatis Recent Development
12Analyst’s Viewpoints/Conclusions
13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Antidepressants
Table 4. Key Players of Anxiolytics
Table 5. Key Players of Anti-manic
Table 6. Key Players of Other
Table 7. Global Drugs for Central Nervous System Diseases Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Drugs for Central Nervous System Diseases Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Drugs for Central Nervous System Diseases Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Drugs for Central Nervous System Diseases Market Share by Regions (2015-2020)
Table 11. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Drugs for Central Nervous System Diseases Market Share by Regions (2021-2026)
Table 13. Drugs for Central Nervous System Diseases Market Market Trends
Table 14. Drugs for Central Nervous System Diseases Market Drivers
Table 15. Drugs for Central Nervous System Diseases Market Challenges
Table 16. Drugs for Central Nervous System Diseases Market Restraints
Table 17. Global Drugs for Central Nervous System Diseases Revenue by Players (2015-2020) (US$ Million)
Table 18. Global Drugs for Central Nervous System Diseases Market Share by Players (2015-2020)
Table 19. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Central Nervous System Diseases as of 2019)
Table 20. Global Drugs for Central Nervous System Diseases by Players Market Concentration Ratio (CR5 and HHI)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Drugs for Central Nervous System Diseases Product Solution and Service
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (US$ Million)
Table 25. Global Drugs for Central Nervous System Diseases Market Size Share by Type (2015-2020)
Table 26. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2021-2026)
Table 27. Global Drugs for Central Nervous System Diseases Market Size Share by Application (2015-2020)
Table 28. Global Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (US$ Million)
Table 29. Global Drugs for Central Nervous System Diseases Market Size Share by Application (2021-2026)
Table 30. North America Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (US$ Million)
Table 31. North America Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 32. North America Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (US$ Million)
Table 33. North America Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 34. North America Drugs for Central Nervous System Diseases Market Size by Country (US$ Million) (2015-2020)
Table 35. North America Drugs for Central Nervous System Diseases Market Share by Country (2015-2020)
Table 36. Europe Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (US$ Million)
Table 37. Europe Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 38. Europe Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (US$ Million)
Table 39. Europe Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 40. Europe Drugs for Central Nervous System Diseases Market Size by Country (US$ Million) (2015-2020)
Table 41. Europe Drugs for Central Nervous System Diseases Market Share by Country (2015-2020)
Table 42. China Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (US$ Million)
Table 43. China Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 44. China Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (US$ Million)
Table 45. China Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 46. China Drugs for Central Nervous System Diseases Market Size by Region (US$ Million) (2015-2020)
Table 47. China Drugs for Central Nervous System Diseases Market Share by Region (2015-2020)
Table 48. Japan Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (US$ Million)
Table 49. Japan Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 50. Japan Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (US$ Million)
Table 51. Japan Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 52. Japan Drugs for Central Nervous System Diseases Market Size by Country (US$ Million) (2015-2020)
Table 53. Japan Drugs for Central Nervous System Diseases Market Share by Country (2015-2020)
Table 54. Southeast Asia Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (US$ Million)
Table 55. Southeast Asia Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 56. Southeast Asia Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (US$ Million)
Table 57. Southeast Asia Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 58. Southeast Asia Drugs for Central Nervous System Diseases Market Size by Country (US$ Million) (2015-2020)
Table 59. Southeast Asia Drugs for Central Nervous System Diseases Market Share by Country (2015-2020)
Table 60. Alkermes Company Details
Table 61. Alkermes Business Overview
Table 62. Alkermes Product
Table 63. Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 64. Alkermes Recent Development
Table 65. Astrazeneca Company Details
Table 66. Astrazeneca Business Overview
Table 67. Astrazeneca Product
Table 68. Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 69. Astrazeneca Recent Development
Table 70. Biogen Company Details
Table 71. Biogen Business Overview
Table 72. Biogen Product
Table 73. Biogen Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 74. Biogen Recent Development
Table 75. Bristol Myers Squibb Company Details
Table 76. Bristol Myers Squibb Business Overview
Table 77. Bristol Myers Squibb Product
Table 78. Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 79. Bristol Myers Squibb Recent Development
Table 80. Lilly Company Details
Table 81. Lilly Business Overview
Table 82. Lilly Product
Table 83. Lilly Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 84. Lilly Recent Development
Table 85. GSK Company Details
Table 86. GSK Business Overview
Table 87. GSK Product
Table 88. GSK Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 89. GSK Recent Development
Table 90. Merck Company Details
Table 91. Merck Business Overview
Table 92. Merck Product
Table 93. Merck Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 94. Merck Recent Development
Table 95. Sunovion Pharmaceuticals Business Overview
Table 96. Sunovion Pharmaceuticals Product
Table 97. Sunovion Pharmaceuticals Company Details
Table 98. Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 99. Sunovion Pharmaceuticals Recent Development
Table 100. Pfizer Company Details
Table 101. Pfizer Business Overview
Table 102. Pfizer Product
Table 103. Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 104. Pfizer Recent Development
Table 105. Teva Company Details
Table 106. Teva Business Overview
Table 107. Teva Product
Table 108. Teva Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 109. Teva Recent Development
Table 110. Norvatis Company Details
Table 111. Norvatis Business Overview
Table 112. Norvatis Product
Table 113. Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (US$ Million)
Table 114. Norvatis Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Central Nervous System Diseases Market Share by Type: 2020 VS 2026
Figure 2. Antidepressants Features
Figure 3. Anxiolytics Features
Figure 4. Anti-manic Features
Figure 5. Other Features
Figure 6. Global Drugs for Central Nervous System Diseases Market Share by Application: 2020 VS 2026
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Drugs for Central Nervous System Diseases Report Years Considered
Figure 11. Global Drugs for Central Nervous System Diseases Market Size (US$ Million), YoY Growth 2015-2026
Figure 12. Global Drugs for Central Nervous System Diseases Market Share by Regions: 2020 VS 2026
Figure 13. Global Drugs for Central Nervous System Diseases Market Share by Regions (2021-2026)
Figure 14. Global Drugs for Central Nervous System Diseases Market Share by Players in 2019
Figure 15. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Central Nervous System Diseases as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Drugs for Central Nervous System Diseases Revenue in 2019
Figure 17. North America Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 18. United States Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. Canada Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. Europe Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Germany Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. France Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. U.K. Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Italy Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Russia Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Nordic Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Rest of Europe Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Asia-Pacific Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. China Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Japan Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. South Korea Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Southeast Asia Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. India Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Australia Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Rest of Asia-Pacific Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Latin America Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Mexico Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Brazil Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Middle East & Africa Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Turkey Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Saudi Arabia Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. UAE Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Rest of Middle East & Africa Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. Alkermes Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 45. Astrazeneca Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 46. Biogen Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 47. Bristol Myers Squibb Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 48. Lilly Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 49. GSK Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 50. Merck Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 51. Sunovion Pharmaceuticals Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 52. Pfizer Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 53. Teva Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 54. Norvatis Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
中枢神経系（CNS）治療の世界市場（～2026年） A central nervous system (CNS) disease can affect either the brain or the spinal cord which leads to neurological or psychiatric disorders. Advancements in diagnostics, therapeutics and drug discovery techniques will further trigger the growth of central nervous system therapeutic market. Market Ana…- 希少性肺疾患治療の世界市場（～2026年） Orphan illnesses are those which are not generally looked into, those where particular medicines are not accessible, and those which may just be of restricted enthusiasm to researchers and specialists. Orphan lung diseases are exemplified by the purported disregarded infectious diseases, which are e…
- 非ステロイド性抗炎症薬（NSAID）の世界市場（～2026年） Nonsteroidal anti-inflammatory drugs (NSAIDs) are a drug class that reduce pain, decrease fever, prevent blood clots and, in higher doses, decrease inflammation. Side effects depend on the specific drug, but largely include an increased risk of gastrointestinal ulcers and bleeds, heart attack and ki…
- 慢性肝疾患治療薬の世界市場（～2026年） Market Analysis and Insights: Global Chronic Liver Diseases Therapeutics Market The global Chronic Liver Diseases Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and hig…
- バーター症候群治療薬の世界市場（～2026年） Bartter syndrome is a rare genetic disorder that causes specific defects in kidney function. Market Analysis and Insights: Global Bartter Syndrome Drugs Market The global Bartter Syndrome Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% d…